Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

14.11 -0.38 (-2.62%)
Streaming Delayed Price Updated: 11:19 AM EST, Feb 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Amneal Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 Next >
News headline image
Amneal Reports Fourth Quarter and Full Year 2025 Financial Results
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol
Represents second complex respiratory therapeutic product approval in Q4 2025 
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal to Participate in Upcoming Investor Conferences
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Receives U.S. FDA Approval for Iohexol Injection
First-to-market complex injectable with expected launch in Q1 2026 
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Reports Third Quarter 2025 Financial Results
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol
Company’s first metered-dose inhalation (MDI) product and establishes a new growth vector for the Affordable Medicines segment 
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab)
From Kashiv BioSciences, LLC and Amneal Pharmaceuticals, Inc. and Alvotech and Advanz Pharma
Via Business Wire
News headline image
Amneal to Report Third Quarter 2025 Results on October 30, 2025
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)
Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver for Amneal 
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%
Important ophthalmic treatment for patients and expected to be a key growth driver for Amneal’s Affordable Medicines segment 
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution
Expands Amneal’s Affordable Medicines portfolio and broadens patient access 
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Reports Second Quarter 2025 Financial Results
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal to Report Second Quarter 2025 Results on August 5, 2025
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal to Participate at Upcoming Investor Conferences in June
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Reports First Quarter 2025 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month
From Amneal Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.